Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset

 
• By Jung Won Shin

Roivant Sciences has added iNtRON Biotechnology’s novel biologic candidate to its existing anti-infective portfolio in a sizable licensing deal amid recent increased global health attention on antimicrobial resistance issues but generally decreasing pharma industry interest.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Roivant Licenses In Novel Korean Anti-infective • Source: Shutterstock

More from South Korea

More from Focus On Asia